BioTuesdays

Category - Markets

Avivagen issues letter to shareholders

In a letter to shareholders, Cameron Groome, CEO of Avivagen (TSX-V:VIV), provided and update about the company and its business plans.Mr. Groome said Avivagen continues the process of commercializing its non-antibiotic...

WB starts Accelerate Diagnostics at outperform

William Blair has launched coverage of Accelerate Diagnostics (NASDAQ:AXDX) with an “outperform” rating and an “aggressive growth” company profile. The stock closed at $19.97 on Thursday.Analyst Brian Weinstein writes...

HCW starts Codexis at buy

H.C. Wainwright has launched coverage of Codexis (NASDAQ:CDXS) with a “buy” rating and $6 price target. The stock closed at $4.23 on Tuesday.Codexis is a biotechnology services company that specializes in the...

JMP resumes coverage of Novadaq at outperform

JMP Securities has resumed coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “market outperform” rating and $16 price target. The stock closed at $13.50 on Tuesday.“Novadaq was once highly regarded within...

Stifel ups Cynosure price target to $50

Stifel has raised its price target for Cynosure (NASDAQ:CYNO) to $50 from $44, reflecting revised estimates and an increased sales multiple due to the company’s higher growth rate. The stock closed at $42 on Monday...

Roth starts Prima BioMed at buy

Roth Capital Partners has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and price target of $6. The stock closed at $1.11 on Wednesday.“We believe Prima is in a leading position in the development...

Roth starts TetraLogic Pharma at buy

Roth Capital Partners has launched coverage of TetraLogic Pharmaceutics (NASDAQ:TLOG) with a “buy” rating and price target of $5. The stock closed at $1.42 on Wednesday.Analyst Joseph Pantginis writes that TetraLogic is...

Oramed closes licensing, investment deal in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has closed a license and investment deal with Hefei Tianhui Incubation of Technologies (HTIT) of China.Oramed has sold 1,155,367 restricted common shares to HTIT at a price of $10.39...

Subscribe

Sign up to our weekly BioTuesdays newsletter.